Fulvestrant Injection, Solution
Product Images NDC 70700-284

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Fulvestrant (NDC 70700-284). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xiromed, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Carton-label.jpg (Carton Fulv 5ml)

Carton-label.jpg (Carton Fulv 5ml)
FDA Label Image

Container Label

Container Label
This appears to be a description of a pharmaceutical product called "Fulvestrant Injection" indicated for intramuscular use only. The injection comes in a single-dose prefilled syringe, and two syringes should be administered to receive the recommended dose of 500 mg. The NDC number for this product is 70700-284-98, and it is manufactured for Xiromed, LLC in Florham Park, NJ. There are also measurements listed in millimeters, but it is not clear what they refer to.*
FDA Label Image

Figure-1 (Fulvestrant Inj Fig 1)

Figure-1 (Fulvestrant Inj Fig 1)
FDA Label Image

Figure-10 (Fulvestrant Inj Fig 10)

Figure-10 (Fulvestrant Inj Fig 10)
FDA Label Image

Figure-11 (Fulvestrant Inj Fig 11)

Figure-11 (Fulvestrant Inj Fig 11)
FDA Label Image

Figure-12 (Fulvestrant Inj Fig 12)

Figure-12 (Fulvestrant Inj Fig 12)
The text represents a Survival Probability Graph comparing the effectiveness of two treatments - FULVESTRANT plus Abemaciclib and FULVESTRANT plus Placebo on a sample size of 446 and 223 respectively. However, due to 100 censored observations, the time scale and the data are not fully available to generate a full interpretation of the survival rate.*
FDA Label Image

Figure-13 (Fulvestrant Inj Fig 13)

Figure-13 (Fulvestrant Inj Fig 13)
FDA Label Image

Figure-14 (Fulvestrant Inj Fig 14)

Figure-14 (Fulvestrant Inj Fig 14)
FDA Label Image

Figure-2 (Fulvestrant Inj Fig 2)

Figure-2 (Fulvestrant Inj Fig 2)
FDA Label Image

Figure-3 (Fulvestrant Inj Fig 3)

Figure-3 (Fulvestrant Inj Fig 3)
FDA Label Image

Figure-4 (Fulvestrant Inj Fig 4)

Figure-4 (Fulvestrant Inj Fig 4)
FDA Label Image

Figure-5 (Fulvestrant Inj Fig 5)

Figure-5 (Fulvestrant Inj Fig 5)
FDA Label Image

Figure-6 (Fulvestrant Inj Fig 6)

Figure-6 (Fulvestrant Inj Fig 6)
The text describes a table showing the number of patients at risk over time (in months) for two different doses of a medication called Fulvestrant (250mg and 500mg). The table seems to show the number of patients who completed the study without experiencing an event, for each time interval.*
FDA Label Image

Figure-7 (Fulvestrant Inj Fig 7)

Figure-7 (Fulvestrant Inj Fig 7)
FDA Label Image

Figure-8 (Fulvestrant Inj Fig 8)

Figure-8 (Fulvestrant Inj Fig 8)
FDA Label Image

Figure-9 (Fulvestrant Inj Fig 9)

Figure-9 (Fulvestrant Inj Fig 9)
FDA Label Image

Structure (Fulvestrant Inj Structure)

Structure (Fulvestrant Inj Structure)
FDA Label Image
Xiromed-logo (Xiromed Logo)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.